A carregar...
Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
OBJECTIVE: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naïve rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX). METHODS: This retrospective nationwide...
Na minha lista:
| Publicado no: | Patient Prefer Adherence |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751906/ https://ncbi.nlm.nih.gov/pubmed/26917952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S94396 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|